News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Continues Its Streak, Phase 2 Breast Cancer Results Wows Investors And Researchers


4/7/2014 6:29:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.

The Phase 2 study, which involved women with the most common form of breast cancer, found that those treated with hormone drug letrozole plus Pfizer's palbociclib lived for an average of 20.2 months before their cancer progressed, compared with 10.2 months for patients given letrozole alone.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Wall Street Journal
Read at Boston Globe
Read at Fox News
Read at Bloomberg


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES